Cerus
Cerus' revenue rose 16.1% to $234 million in fiscal 2025. Its operating margin was −3.7%, up from −7.1% a year earlier. Free cash flow was $1 million, down 87.0%. The diluted share count rose 3.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Cerus does
Cerus develops and sells the INTERCEPT Blood System, a set of products that reduce viruses, bacteria and parasites in donated blood before it is given to patients. It is used with platelets, which help blood clot, and with plasma, the liquid part of blood. It also makes a fibrinogen product used to treat serious bleeding.
The platelet and plasma systems have FDA approval in the United States and the European CE Mark, and are sold in the U.S., parts of Europe, the Middle East, Latin America and other regions. Buyers are blood centers and hospitals. Cerus also earns revenue from U.S. government contracts, including with BARDA and the Department of Defense, which help pay for its development work.
A version for red blood cells is not yet sold anywhere. It is in a late-stage clinical trial, and its European approval application has had to be resubmitted. Cerus relies on Fresenius Kabi and other outside companies to make parts of the system. The company was founded in California in 1991 and now has a Dutch subsidiary.
Its biggest risks, as it describes them
- The red blood cell system may never win approvals or European certification.
- Its development funding depends in part on U.S. government agreements that could be cut or ended.
- It relies on Fresenius Kabi and other third parties to make parts of its system.
- It expects continued losses and has limited sales and marketing experience in the U.S.
- Its system may not be compatible with some commercial platelet collection methods.
Income statement
Cerus lost money in fiscal 2025: a net loss of $16 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 129 | 102 | 66 | 80 | 83 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −9.9x | −5.8x | −3.6x | −1.6x | −1.0x |
| Current ratio | 2.4x | 1.4x | 2.1x | 2.4x | 1.7x |
| Quick ratio | 2.0x | 1.2x | 1.6x | 1.8x | 1.2x |
Cash flow
Projections
Project Cerus' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Cerus says to expect
- Full year 2026: product revenue
The Company continues to expect full-year 2026 product revenue to be in the range of $229 million to $231 million, reflecting growth of 11% to 12% from 2025. Included in this range is full-year 2026 IFC revenue guidance of $23 million to $25 million.
Insider trades
No officer, director or 10% owner of Cerus reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −26.4% | 12.0% | 16.6% |
| Altman Z'' | −15.30 | −14.46 | −13.54 |
| Accruals ratio | 2.7% | −16.2% | −9.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Cerus side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Cerus | FY25 | 16.1% | −3.7% | 0.5% | — | — | — | |
| Orthopediatrics | FY25 | 15.4% | −16.6% | −6.8% | −8.2% | — | 4 | Compare |
| STAAR Surgical | FY25 | −23.7% | −38.3% | −16.7% | — | — | — | Compare |
| Axogen | FY25 | 20.2% | −3.5% | −1.3% | −4.9% | — | 5 | Compare |
| LeMaitre Vascular | FY25 | 13.5% | 27.2% | 29.8% | 25.5% | −2.4x | 5 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 39 | 51 | 76 | 94 | 114 | 160 | 188 | 187 | 201 | 234 |
| Revenue growth | 14.8% | 30.7% | 48.2% | 23.3% | 21.8% | 39.6% | 18.1% | −0.8% | 7.8% | 16.1% |
| Gross profit | 17 | 29 | 44 | 60 | 73 | — | — | — | — | — |
| Research and development | 31 | 34 | 43 | 60 | 64 | 64 | 64 | 68 | 59 | 68 |
| Operating income | −61 | −58 | −55 | −66 | −58 | −49 | −34 | −30 | −14 | −9 |
| Net income | −63 | −61 | −58 | −71 | −60 | −54 | −43 | −38 | −21 | −16 |
| Diluted EPS (US$) | −0.62 | −0.56 | −0.44 | −0.51 | −0.37 | −0.32 | −0.24 | −0.21 | −0.11 | −0.08 |
| Diluted shares (millions) | 102 | 108 | 132 | 140 | 164 | 171 | 176 | 180 | 185 | 191 |
| Cash flow | ||||||||||
| Cash from operations | −54 | −52 | −31 | −66 | −42 | −34 | −26 | −43 | 11 | 5 |
| Capital expenditure | 1 | 0 | 1 | 9 | 2 | 1 | 2 | 5 | 3 | 4 |
| Free cash flow | −54 | −53 | −32 | −74 | −43 | −35 | −28 | −48 | 9 | 1 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 8 | 9 | 10 | 13 | 18 | 24 | 24 | 20 | 23 | 23 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 68 | 61 | 118 | 86 | 134 | 129 | 102 | 66 | 80 | 83 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 104 | 98 | 164 | 166 | 221 | 238 | 218 | 198 | 201 | 222 |
| Total liabilities | 46 | 59 | 79 | 108 | 118 | 152 | 150 | 144 | 144 | 157 |
| Shareholders' equity | 58 | 39 | 84 | 57 | 104 | 85 | 68 | 53 | 56 | 64 |
| Margins and ratios | ||||||||||
| Gross margin | 43.0% | 56.1% | 58.4% | 64.4% | 64.0% | — | — | — | — | — |
| Operating margin | −156.4% | −112.1% | −72.3% | −70.6% | −51.1% | −30.7% | −18.1% | −16.1% | −7.1% | −3.7% |
| Net margin | −160.2% | −118.0% | −75.7% | −76.0% | −52.4% | −34.1% | −22.7% | −20.1% | −10.4% | −6.7% |
| Free cash flow margin | −137.7% | −102.5% | −42.6% | −79.4% | −38.0% | −21.8% | −14.7% | −25.6% | 4.2% | 0.5% |
| Rule of 40 (growth + FCF margin) | −123.0% | −71.8% | 5.6% | −56.1% | −16.2% | 17.8% | 3.4% | −26.4% | 12.0% | 16.6% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −82.5% | −125.3% | −93.2% | −100.7% | −74.4% | −57.7% | −56.2% | −62.4% | −38.5% | −26.0% |
| Return on assets | −51.8% | −60.1% | −44.0% | −43.3% | −30.9% | −23.7% | −18.8% | −18.0% | −10.5% | −7.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |